Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ossium
- Development stage
- Preclinical
- Lead developer
- Ossium Health
- Modality
- Cell Therapies
- Administration
- Oral, Sublingual
01
Overview
Ossium is a product developed by Ossium Health, comprising cryopreserved hematopoietic progenitor cells (HPCs) and mesenchymal stem cells (MSCs) derived from the vertebral bodies of deceased organ donors. These cells are banked for on-demand use in allogeneic hematopoietic cell transplantation (HCT) as an alternative graft source. The product aims to reconstitute the hematopoietic system. Additionally, matched vertebral bone adherent MSCs (vBA-MSC) are intended to facilitate chimerism, promote immunomodulation, and enhance the safety of bone marrow infusions, with potential applications in inducing immune tolerance for solid organ and vascular composite allografts.
- Other names
- Ossium's HPC, MarrowOssium Mesenchymal Stem CellsOssium HPCs from BM
Beyond the preview
Go deeper on Ossium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ossium.